PubMed Central, : RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2022; 13(4): e0026. ISSN: 2076-9172Published online 2022 October 27. doi: 10.5041/RMMJ.10485.

Table 2.

Cannabis Dosage During the Study and Adverse Effects.

Time-point	g/Month	Pts (n)	%THC:%CBD	Males:Females	Adverse Events
M0 (WO1)	--	24	--	17:7
P1 M1	20	24	05THC:30CBD	17:7	Nausea, drowsiness, dizziness, fatigue
P1 M3	30	23	05THC:30CBD	16:7	Nausea, drowsiness, dizziness, fatigue
P1 M6	30	21	05THC:30CBD	16:5	Nausea, drowsiness, dizziness, fatigue
P2 M11 (WO2)	--	21	--	17:7	None
P2 M12	20	24	10THC:10CBD	17:7	Drowsiness, sore throat
P2 M18	30	20	20THC:04CBD	15:5	None
	40	2	20THC:04CBD	2 males	None
	20	2	10THC:10CBD	2 females	None
P2 M24	30	10	20THC:04CBD	5:5	None
	40	7	20THC:04CBD	7 males	None
	50	3	20THC:04CBD	3 males	None
	60	2	20THC:04CBD	2 males	None
	20	2	10THC:10CBD	2 females	None

M, month; M0, month 0 (before study start); P1, phase 1 of study (extract therapy); P2, phase 2 of study (smoked); Pts, patients.

RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2022; 13(4): e0026. ISSN: 2076-9172

Published online 2022 October 27. doi: 10.5041/RMMJ.10485